Sight Sciences to Present at Citi’s 2025 Unplugged MedTech and Life Sciences Access Day
Sight Sciences (Nasdaq: SGHT), an eyecare technology company, has announced its participation in Citi's 2025 Unplugged MedTech and Life Sciences Access Day in New York. The company, which specializes in developing innovative interventional technologies for eye care, will deliver a presentation on Thursday, February 27, 2025, at 7:15 am PT / 10:15 am ET.
Investors and interested parties can access both the live presentation and archived webcast through the company's investor relations website at investors.sightsciences.com. This presentation represents an opportunity for stakeholders to gain insights into the company's developments and strategies in transformative eye care solutions.
Sight Sciences (Nasdaq: SGHT), un'azienda tecnologica nel settore della cura degli occhi, ha annunciato la sua partecipazione a Citi's 2025 Unplugged MedTech and Life Sciences Access Day a New York. L'azienda, specializzata nello sviluppo di tecnologie interventistiche innovative per la cura degli occhi, presenterà il suo intervento giovedì 27 febbraio 2025, alle 7:15 PT / 10:15 ET.
Investitori e parti interessate possono accedere sia alla presentazione dal vivo che alla registrazione del webcast attraverso il sito web delle relazioni con gli investitori dell'azienda all'indirizzo investors.sightsciences.com. Questa presentazione rappresenta un'opportunità per gli stakeholder di ottenere informazioni sugli sviluppi e le strategie dell'azienda nel campo delle soluzioni trasformative per la cura degli occhi.
Sight Sciences (Nasdaq: SGHT), una empresa de tecnología en el cuidado ocular, ha anunciado su participación en Citi's 2025 Unplugged MedTech and Life Sciences Access Day en Nueva York. La empresa, que se especializa en el desarrollo de tecnologías intervencionistas innovadoras para el cuidado de los ojos, realizará una presentación el jueves 27 de febrero de 2025, a las 7:15 am PT / 10:15 am ET.
Los inversores y partes interesadas pueden acceder tanto a la presentación en vivo como a la grabación del webcast a través del sitio web de relaciones con inversores de la empresa en investors.sightsciences.com. Esta presentación representa una oportunidad para que las partes interesadas obtengan información sobre los desarrollos y estrategias de la empresa en soluciones transformadoras para el cuidado ocular.
사이트 사이언스(Sight Sciences) (Nasdaq: SGHT), 안과 기술 회사가 뉴욕에서 열리는 Citi's 2025 Unplugged MedTech and Life Sciences Access Day에 참여한다고 발표했습니다. 이 회사는 안과 치료를 위한 혁신적인 중재 기술 개발을 전문으로 하며, 2025년 2월 27일 목요일, 오전 7:15 PT / 오전 10:15 ET에 발표를 진행할 예정입니다.
투자자 및 관심 있는 당사자는 회사의 투자자 관계 웹사이트인 investors.sightsciences.com를 통해 실시간 발표 및 아카이브된 웹캐스트에 접근할 수 있습니다. 이 발표는 이해관계자들이 회사의 개발 및 변혁적인 안과 치료 솔루션에 대한 전략을 이해할 수 있는 기회를 제공합니다.
Sight Sciences (Nasdaq: SGHT), une entreprise de technologie dans le domaine des soins oculaires, a annoncé sa participation à Citi's 2025 Unplugged MedTech and Life Sciences Access Day à New York. L'entreprise, spécialisée dans le développement de technologies interventionnelles innovantes pour les soins oculaires, fera une présentation jeudi 27 février 2025, à 7h15 PT / 10h15 ET.
Les investisseurs et les parties intéressées peuvent accéder à la fois à la présentation en direct et au webcast archivé via le site web des relations avec les investisseurs de l'entreprise à l'adresse investors.sightsciences.com. Cette présentation représente une opportunité pour les parties prenantes d'obtenir des informations sur les développements et les stratégies de l'entreprise dans le domaine des solutions de soins oculaires transformantes.
Sight Sciences (Nasdaq: SGHT), ein Technologieunternehmen im Bereich Augenheilkunde, hat seine Teilnahme an Citi's 2025 Unplugged MedTech and Life Sciences Access Day in New York angekündigt. Das Unternehmen, das sich auf die Entwicklung innovativer interventioneller Technologien für die Augenheilkunde spezialisiert hat, wird am Donnerstag, den 27. Februar 2025, um 7:15 Uhr PT / 10:15 Uhr ET eine Präsentation halten.
Investoren und Interessierte können sowohl die Live-Präsentation als auch das archivierte Webcast über die Investor-Relations-Website des Unternehmens unter investors.sightsciences.com abrufen. Diese Präsentation bietet den Stakeholdern die Möglichkeit, Einblicke in die Entwicklungen und Strategien des Unternehmens im Bereich transformierender Augenheillösungen zu gewinnen.
- None.
- None.
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at Citi’s 2025 Unplugged MedTech and Life Sciences Access Day, in New York, NY.
Sight Sciences’ management is scheduled to present on Thursday, February 27, 2025, at 7:15 am PT / 10:15 am ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the Company’s website at https://investors.sightsciences.com/.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (“MGD”), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.
Sight Sciences, the Sight Sciences logo, TearCare, SmartHub and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.
© 2025 Sight Sciences. All rights reserved.
Media contact:
pr@sightsciences.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
investor.relations@sightsciences.com
FAQ
When is Sight Sciences (SGHT) presenting at Citi's 2025 Unplugged MedTech conference?
How can investors watch Sight Sciences' (SGHT) presentation at the Citi 2025 conference?
What type of technologies does Sight Sciences (SGHT) develop?
Where is the Citi 2025 Unplugged MedTech conference featuring SGHT being held?
